Macrobiome Therapeutics is an Australian-based biotechnology company with a unique platform technology and immunology assets inspired by host-parasite co-evolution. Parasitic worms have evolved to survive in their vertebrate hosts while causing minimal pathology, a relationship that has been fine tuned for millions of years. The company has access to human specimens and data generated by the founders who routinely conduct clinical trials using experimental hookworm therapy in patients with immune disorders. The company’s mission is to identify biomarkers of efficacy from these clinical trials and then search for worm secreted proteins with the desired bioactivities. We have developed numerous recombinant proteins that protect in animal models of IBD, rheumatoid arthritis and asthma, and show ex vivo bioactivity with relevant human tissues. Macrobiome's goal is to develop novel next-gen therapeutics inspired by evolutionary biology to combat the epidemic of immune dysfunction diseases.